Key Points
- Jordan Clark bought 100 shares on March 2 at GBX 150 (total £150) and had previously purchased 117 shares on Dec 23 at GBX 128 (total £149.76).
- Shore Capital raised its target to GBX 215 and gave a "Buy" rating; three analysts rate the stock Buy with an average price target of GBX 193.33.
- Diaceutics opened at GBX 145.50, has a market cap of £123.13m, a 12‑month range of GBX 106–176.25, and a negative P/E of -80.83.
Diaceutics PLC (LON:DXRX - Get Free Report) insider Jordan Clark acquired 100 shares of the business's stock in a transaction that occurred on Monday, March 2nd. The shares were bought at an average price of GBX 150 per share, with a total value of £150.
Jordan Clark also recently made the following trade(s):
- On Tuesday, December 23rd, Jordan Clark bought 117 shares of Diaceutics stock. The stock was purchased at an average cost of GBX 128 per share, with a total value of £149.76.
Diaceutics Price Performance
LON DXRX opened at GBX 145.50 on Friday. The company has a current ratio of 3.96, a quick ratio of 9.92 and a debt-to-equity ratio of 3.05. Diaceutics PLC has a 12 month low of GBX 106 and a 12 month high of GBX 176.25. The stock has a market cap of £123.13 million, a price-to-earnings ratio of -80.83 and a beta of 0.58. The company's 50 day moving average is GBX 153.42 and its two-hundred day moving average is GBX 151.80.
Wall Street Analyst Weigh In
Separately, Shore Capital Group upped their target price on shares of Diaceutics from GBX 180 to GBX 215 and gave the stock a "buy" rating in a report on Thursday, January 15th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of GBX 193.33.
Get Our Latest Analysis on Diaceutics
Diaceutics Company Profile
(
Get Free Report)
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
